259 related articles for article (PubMed ID: 28165586)
1. Efficacy of postoperative polymyxin B hemoperfusion in secondary peritonitis patients with septic shock: a propensity-matched analysis.
Yuan KC; Wang SY; Yu MC; Hsu YP; Pan HC; Chen YC
Int J Artif Organs; 2017 Feb; 39(12):603-610. PubMed ID: 28165586
[TBL] [Abstract][Full Text] [Related]
2. Effects of Polymyxin B Hemoperfusion on Septic Shock Patients Requiring Noradrenaline: Analysis of a Nationwide Administrative Database in Japan.
Fujimori K; Tarasawa K; Fushimi K
Blood Purif; 2021; 50(4-5):560-565. PubMed ID: 33582663
[TBL] [Abstract][Full Text] [Related]
3. Early use of polymyxin B hemoperfusion in patients with septic shock due to peritonitis: a multicenter randomized control trial.
Payen DM; Guilhot J; Launey Y; Lukaszewicz AC; Kaaki M; Veber B; Pottecher J; Joannes-Boyau O; Martin-Lefevre L; Jabaudon M; Mimoz O; Coudroy R; Ferrandière M; Kipnis E; Vela C; Chevallier S; Mallat J; Robert R;
Intensive Care Med; 2015 Jun; 41(6):975-84. PubMed ID: 25862039
[TBL] [Abstract][Full Text] [Related]
4. Potential survival benefit of polymyxin B hemoperfusion in patients with septic shock: a propensity-matched cohort study.
Nakamura Y; Kitamura T; Kiyomi F; Hayakawa M; Hoshino K; Kawano Y; Yamasaki R; Nishida T; Mizunuma M; Ishikura H;
Crit Care; 2017 Jun; 21(1):134. PubMed ID: 28592318
[TBL] [Abstract][Full Text] [Related]
5. Polymyxin B-immobilized fiber column hemoperfusion therapy for septic shock.
Mitaka C; Tomita M
Shock; 2011 Oct; 36(4):332-8. PubMed ID: 21654557
[TBL] [Abstract][Full Text] [Related]
6. Removal of 2-arachidonylglycerol by direct hemoperfusion therapy with polymyxin B immobilized fibers benefits patients with septic shock.
Kase Y; Obata T; Okamoto Y; Iwai K; Saito K; Yokoyama K; Takinami M; Tanifuji Y
Ther Apher Dial; 2008 Oct; 12(5):374-80. PubMed ID: 18937720
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness analysis of polymyxin-B immobilized fiber column and conventional medical therapy in the management of abdominal septic shock in Italy.
Berto P; Ronco C; Cruz D; Melotti RM; Antonelli M
Blood Purif; 2011; 32(4):331-40. PubMed ID: 22086346
[TBL] [Abstract][Full Text] [Related]
8. A longer duration of polymyxin B-immobilized fiber column hemoperfusion improves pulmonary oxygenation in patients with septic shock.
Mitaka C; Tsuchida N; Kawada K; Nakajima Y; Imai T; Sasaki S
Shock; 2009 Nov; 32(5):478-83. PubMed ID: 19295483
[TBL] [Abstract][Full Text] [Related]
9. VASOPRESSOR REDUCTION EFFECT OF POLYMYXIN B HEMOPERFUSION IN PATIENTS WITH PERITONITIS-INDUCED SEPTIC SHOCK: A PROPENSITY SCORE-MATCHED ANALYSIS.
Cho A; Oh SY; Lee H; Ryu HG
Shock; 2024 Jul; 62(1):69-73. PubMed ID: 38661146
[TBL] [Abstract][Full Text] [Related]
10. Endotoxin adsorption therapy for septic shock using polymyxin B-immobilized fibers (PMX): evaluation by high-sensitivity endotoxin assay and measurement of the cytokine production capacity.
Kojika M; Sato N; Yaegashi Y; Suzuki Y; Suzuki K; Nakae H; Endo S
Ther Apher Dial; 2006 Feb; 10(1):12-8. PubMed ID: 16556131
[TBL] [Abstract][Full Text] [Related]
11. Early induction of direct hemoperfusion with a polymyxin-B immobilized column is associated with amelioration of hemodynamic derangement and mortality in patients with septic shock.
Chihara S; Masuda Y; Tatsumi H; Nakano K; Shimada T; Murohashi T; Yamakage M
J Artif Organs; 2017 Mar; 20(1):71-75. PubMed ID: 27469940
[TBL] [Abstract][Full Text] [Related]
12. Urinary liver-type fatty acid-binding protein in septic shock: effect of polymyxin B-immobilized fiber hemoperfusion.
Nakamura T; Sugaya T; Koide H
Shock; 2009 May; 31(5):454-9. PubMed ID: 18838948
[TBL] [Abstract][Full Text] [Related]
13. Exacerbation of prothrombin time-international normalized ratio before second polymyxin B cartridge hemoperfusion predicts poor outcome of patients with severe sepsis and/or septic shock.
Ishizuka M; Terasaki A; Kubota K
J Surg Res; 2016 Jan; 200(1):308-14. PubMed ID: 26319975
[TBL] [Abstract][Full Text] [Related]
14. Evidence and Perspectives on the Use of Polymyxin B-Immobilized Fiber Column Hemoperfusion among Critically Ill Patients.
Yamashita C; Moriyama K; Hasegawa D; Hara Y; Kuriyama N; Nakamura T; Shibata J; Komura H; Nishida O
Contrib Nephrol; 2018; 196():215-222. PubMed ID: 30041230
[TBL] [Abstract][Full Text] [Related]
15. Polymyxin B-immobilised haemoperfusion and mortality in critically ill patients with sepsis/septic shock: a protocol for a systematic review and meta-analysis.
Fujii T; Ganeko R; Kataoka Y; Featherstone R; Bagshaw SM; Furukawa TA
BMJ Open; 2016 Nov; 6(11):e012908. PubMed ID: 27872122
[TBL] [Abstract][Full Text] [Related]
16. Clinical Effects of Polymyxin B Hemoperfusion in Patients With Septic Shock Caused by Urinary Tract Infection.
Suzuki Y; Kojika M; Sato H; Inoue Y; Endo S
Ther Apher Dial; 2019 Feb; 23(1):80-85. PubMed ID: 30209889
[TBL] [Abstract][Full Text] [Related]
17. Therapeutic Rationale for Endotoxin Removal with Polymyxin B Immobilized Fiber Column (PMX) for Septic Shock.
Shoji H; Opal SM
Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33672437
[TBL] [Abstract][Full Text] [Related]
18. Endotoxin removal by direct hemoperfusion with an adsorbent column using polymyxin B-immobilized fiber ameliorates systemic circulatory disturbance in patients with septic shock.
Uriu K; Osajima A; Hiroshige K; Watanabe H; Aibara K; Inada Y; Segawa K; Anai H; Takagi I; Ito A; Kamochi M; Kaizu K
Am J Kidney Dis; 2002 May; 39(5):937-47. PubMed ID: 11979337
[TBL] [Abstract][Full Text] [Related]
19. Direct hemoperfusion with polymyxin B-immobilized cartridge in severe sepsis due to intestinal perforation: hemodynamic findings and clinical considerations in anticoagulation therapy.
Maynar J; Martínez-Sagasti F; Herrera-Gutiérrez M; Martí F; Candel FJ; Belda J; Castaño S; Sanchez-Izquierdo JÁ
Rev Esp Quimioter; 2013 Jun; 26(2):151-8. PubMed ID: 23817653
[TBL] [Abstract][Full Text] [Related]
20. Effective combination therapy of polymyxin-B direct hemoperfusion and recombinant thrombomodulin for septic shock accompanied by disseminated intravascular coagulation: a historical controlled trial.
Yamato M; Minematsu Y; Fujii J; Mori K; Minato T; Miyagawa S; Fujimura R; Morikage N; Arata Y; Nakano C; Wada A; Ito T
Ther Apher Dial; 2013 Oct; 17(5):472-6. PubMed ID: 24107274
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
